Invention Grant
- Patent Title: Substituted pyrazines as inhibitors of BTK, and mutants thereof
-
Application No.: US16996516Application Date: 2020-08-18
-
Publication No.: US11501284B2Publication Date: 2022-11-15
- Inventor: Yi Chen
- Applicant: Newave Pharmaceutical Inc.
- Applicant Address: US CA Pleasanton
- Assignee: Newave Pharmaceutical Inc.
- Current Assignee: Newave Pharmaceutical Inc.
- Current Assignee Address: US CA Pleasanton
- Agency: McCarter & English, LLP
- Agent Yu Lu; Zhongyu “Alex” Wang
- Main IPC: A61K31/497
- IPC: A61K31/497 ; C07D241/20 ; G06Q20/34 ; G06K19/07 ; A61P35/04 ; C07D403/04
Abstract:
The disclosure includes compounds of Formula (I) wherein Q1, Q2, Q3, W, X, Y, Z1, m, n, Warhead, R1, R2, R3, R4, and R5, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.
Public/Granted literature
- US20200377478A1 INHIBITORS OF BTK AND MUTANTS THEREOF Public/Granted day:2020-12-03
Information query
IPC分类:
